SCHEMBL350031

SCHEMBL350031

CCOC(=O)Cc1ccc(OC)c(Oc2ccc(N)cc2C(S)c2ccc(Cl)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.41
PDE4B Q07343 1/20 0.40
PDE4D Q08499 1/20 0.40
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38
POLB P06746 1/20 0.37
LMNA P02545 2/20 0.36
PKM P14618 1/20 0.36
CTSD P07339 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL349217 0.84 PTGDR2 (0.49) PTGDR2MAPTPOLBLMNAALDH1A1
SCHEMBL349880 0.82 LMNA (0.39) MAPTL3MBTL1ABL1RIN1LMNA
SCHEMBL350154 0.80 PTGDR2 (0.49) PTGDR2MAPTL3MBTL1POLBLMNA
SCHEMBL350032 0.78 PPARG (0.46) PTGDR2PDE4BPDE4DMAPTL3MBTL1
SCHEMBL13521900 0.77 L3MBTL1 (0.41) MAPTL3MBTL1ABL1RIN1POLB
SCHEMBL13521852 0.76 POLB (0.47) PTGDR2PDE4BPDE4DMAPTL3MBTL1
SCHEMBL348284 0.74 ALOX15 (0.43) PTGDR2PDE4BPDE4DMAPTL3MBTL1
SCHEMBL349018 0.74 POLB (0.45) PTGDR2PDE4BPDE4DMAPTABL1
SCHEMBL348213 0.74 LMNA (0.44) PTGDR2MAPTPOLBLMNAALDH1A1
SCHEMBL349203 0.73 CYP3A4 (0.40) MAPTL3MBTL1ABL1RIN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247602-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-21 US disclosed
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC (US) 2012-01-19 US disclosed
US-8071807-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2011-12-06 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-06-16 US disclosed
EP-2307362-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS Amira Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 US disclosed
WO-2010003120-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 PTGDR2 2/4885PDE4B 694/4885PDE4D 566/4885
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 PTGDR2 2/4885PDE4B 694/4885PDE4D 566/4885
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 PTGDR2 2/4885PDE4B 694/4885PDE4D 566/4885
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 PTGDR2 2/4885PDE4B 794/4885PDE4D 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.